Camidanlumab tesirine is a Monoclonal Antibody Conjugated owned by ADC Therapeutics, and is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing.

Camidanlumab tesirine acts by targeting CD25 (IL-2 receptor alpha chain or TAC). CD25 is a cell-surface antigen, which is over-expressed in tumor cells. On binding with CD25 the therapeutic candidate may activate natural killer (NK) cells and macrophages and may induce T cell cytotoxic immune responses against tumor cells. It induces a long-lived adaptive immune responses against tumor-associated antigens and limits the growth of cancer cells.

The revenue for Camidanlumab tesirine is expected to reach a total of $382m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Camidanlumab tesirine NPV Report.

Camidanlumab tesirine was originated by Genmab and ADC Therapeutics and is currently owned by ADC Therapeutics.

Camidanlumab tesirine Overview

Camidanlumab tesirine is under development for the treatment of CD25-expressing relapsed/refractory Hodgkin lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms, Non-Hodgkin lymphoma. The therapeutic candidate is administered as an intravenous infusion. ADCT-301 is an antibody drug conjugate composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug–antibody ratio of 2.3. It was also under development for prostate cancer, relapsed or refractory CD25-positive acute lymphocytic leukemia (ALL). It was under devlopment for the treatment of advanced solid tumors including head and neck squamous cell carcinoma, fallopian tube cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, pancreas cancer, bladder cancer, renal cell carcinoma, melanoma, triple-negative breast cancer, ovarian cancer and colorectal cancer

ADC Therapeutics Overview

ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.

The company reported revenues of (US Dollars) US$33.9 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$261.7 million in FY2021, compared to an operating loss of US$219.3 million in FY2020. The net loss of the company was US$230 million in FY2021, compared to a net loss of US$246.3 million in FY2020. The company reported revenues of US$76.3 million for the third quarter ended September 2022, compared to a revenue of US$17.3 million the previous quarter.

Quick View – Camidanlumab tesirine

Report Segments
  • Innovator
Drug Name
  • Camidanlumab tesirine
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.